Author

Simbarashe Takuva

School of Health Systems and Public Health, Faculty of Health Sciences, University of Pretoria - Cited by 1,003 - HIV Medicine - Tuberculosis - Clinical Epidemiology - Vaccines

Biography

Dr.Simbarashe Takuva working as a Regional Medical Liaison at Southern Africa HIV Vaccine Trials Network from February 2015 – Present (10 months). Working as a Extraordinary Lecturer at University of Pretoria, School of Health Systems and Public Health from January 2015 – Present (11 months). Working as a Medical EpidemiologistNHLS, at National Institute for Communicable Diseases from December 2012 – January 2015 (2 years 2 months) Worked as a Epidemiologist & Investigator at Clinical HIV Research Unit during June 2009 – November 2012 (3 years 6 months).
Title
Cited by
Year
Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition
L Corey, PB Gilbert, M Juraska, DC Montefiori, L Morris, ST Karuna, ...New England Journal of Medicine 384 (11), 1003-1014, 2021202
221
2021
Vaccine efficacy of ALVAC-HIV and bivalent subtype C gp120–MF59 in adults
GE Gray, LG Bekker, F Laher, M Malahleha, M Allen, Z Moodie, ...New England Journal of Medicine 384 (12), 1089-1100, 2021202
129
2021
Anemia among HIV-infected patients initiating antiretroviral therapy in South Africa: improvement in hemoglobin regardless of degree of immunosuppression and the initiating ART …
S Takuva, M Maskew, AT Brennan, I Sanne, AP MacPhail, MP FoxJournal of tropical medicine 2013, 2013201
66
2013
Poor CD4 recovery and risk of subsequent progression to AIDS or death despite viral suppression in a South African cohort
S Takuva, M Maskew, AT Brennan, L Long, I Sanne, MP FoxJournal of the International AIDS Society 17 (1), 18651, 2014201
55
2014
The continuum of HIV care in South Africa: implications for achieving the second and third UNAIDS 90-90-90 targets
S Takuva, AE Brown, Y Pillay, V Delpech, AJ PurenAids 31 (4), 545-552, 2017201
49
2017
Thromboembolic events in the South African Ad26. COV2. S vaccine study
S Takuva, A Takalani, N Garrett, A Goga, J Peter, V Louw, J Opie, ...New England Journal of Medicine 385 (6), 570-571, 2021202
44
2021
Effectiveness of the Ad26. COV2. S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study
LG Bekker, N Garrett, A Goga, L Fairall, T Reddy, N Yende-Zuma, ...The Lancet 9 (10330), 1141-1153, 2022202
39
2022
Rates of virological suppression and drug resistance in adult HIV-1-positive patients attending primary healthcare facilities in KwaZulu-Natal, South Africa
GM Hunt, EK Dokubo, S Takuva, T de Oliveira, J Ledwaba, N Dube, ...Journal of Antimicrobial Chemotherapy 72 (11), 3141-3148, 2017201
36
2017
HVTN 704/HPTN 085 and HVTN 703/HPTN 081 Study Teams. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition
L Corey, PB Gilbert, M Juraska, DC Montefiori, L Morris, ST Karuna, ...N. Engl. J. Med 384, 1003-1014, 2021202
27
2021
Etiology and antimicrobial susceptibility of pathogens responsible for urethral discharge among men in Harare, Zimbabwe
S Takuva, O Mugurungi, J Mutsvangwa, A Machiha, AC Mupambo, ...Sexually transmitted diseases 41 (12), 713-717, 2014201
26
2014
An association between decreasing incidence of invasive non-typhoidal salmonellosis and increased use of antiretroviral therapy, Gauteng Province, South Africa, 2003–2013
KH Keddy, S Takuva, A Musekiwa, AJ Puren, A Sooka, A Karstaedt, ...PloS one 12 (3), e0173091, 2017201
26
2017
Risk factors for discordant immune response among HIV-infected patients initiating antiretroviral therapy: A retrospective cohort study
BP Muzah, S Takuva, M Maskew, S Delany-MoretlweSouthern African Journal of HIV Medicine 13 (4), 168-172, 2012201
23
2012
Efficacy, safety, and immunogenicity of a booster regimen of Ad26. COV2. S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled …
K Hardt, A Vandebosch, J Sadoff, M Le Gars, C Truyers, D Lowson, ...The Lancet Infectious Diseases (12), 1703-1715, 202
22
2022
CD4 count recovery and associated factors among individuals enrolled in the South African antiretroviral therapy programme: an analysis of national laboratory based data
T Kufa, Z Shubber, W MacLeod, S Takuva, S Carmona, J Bor, M Gorgens, ...PLoS One 14 (5), e0217742, 191
20
2019
A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection in women in sub-Saharan Africa …
NM Mgodi, S Takuva, S Edupuganti, S Karuna, P Andrew, E Lazarus, ...Journal of acquired immune deficiency syndromes (1999) 87 (1), 680, 2021202
17
2021
Incidence and predictors of recovery from anaemia within an HIV-infected South African Cohort, 2004-2010
Z Ndlovu, T Chirwa, S TakuvaPan African Medical Journal 19 (1), 2014201
17
2014
HIV-associated lipodystrophy in South Africa: the impact on the patient and the impact on the plastic surgeon
RJ Zinn, C Serrurier, S Takuva, I Sanne, CN MenezesJournal of Plastic, Reconstructive & Aesthetic Surgery 66 (6), 839-844, 2013201
15
2013
Disparities in engagement within HIV care in South Africa
S Takuva, A Puren, A Brown, V Delpech, W Macleod, Y PillayConference on Retroviruses and Opportunistic Infections, 23-26, 2015201
14
2015
Prevalence and risk factors for self-reported sexually transmitted infections among adults in the Diepsloot informal settlement, Johannesburg, South Africa
TJ Basera, S Takuva, K Muloongo, N Tshuma, PS NyasuluJ AIDS Clin Res 7 (539), 2, 2016201
12
2016
Cameroon Public Expenditure Review: Aligning Public Expenditures with the Goals of Vision 2035
World BankWorld Bank, 201812201
12
2018

Referred From: https://scholar.google.co.in/citations?user=mhtCbG4AAAAJ&hl=en

Cited by
Citations 1003
h-index 17
i10-index 22
Recommended Journals
Open Access Journals